通泰合剂联合XELIRI方案治疗晚期大肠癌的疗效与安全性

The effect of XELIRI regimen with tongtai decoction in patients with advanced colorectal cancer

目的观察通泰合剂联合XELIRI方案治疗晚期大肠癌的疗效与安全性。方法将76个纳入研究的病例进行随机分组,对照组39人,观察组37人,对照组予XELIRI方案;观察组加用通泰合剂,观察两组有效率、免疫功能的改善及化疗副作用的情况。结果观察组及对照组有效率分别为40.54%及28.21%,组间比较无显著差异(P>0.05)。观察组中医症候疗效更优(P<0.05);观察组腹泻的发生率更低(P<0.05);行为能力评分(KPS)比较无差异,生活质量(QOL)改善情况观察组更佳(P<0.05);CEA:治疗后,观察组数值水平显著下降,对照组则无显著性差异。结论通泰合剂联合XELIRI方案治疗晚期大肠癌疗效确切,副作用轻,值得推广。

Objective To investigate the efficacy and safety of XELIRI regimen with tongtai decoction in patients with advanced colorectal cancer. Methods Seventy six patients were included in this study, and 39 patients were assigned to control group to receive XELIRI regimen only, while 37 patients were assigned to observation group to receive XELIRI regimen with tongtai decoction. The efficacy and side effect in two groups were assessed. Results The efficacy in observation group and control group were 40.54% and 23.2]% respectively （P 〉 0.05）. Traditional Chinese Medical symptoms in observation group was better than control group （P 〈 0.05）. The patients in observation group had a lower the incidence of diarrhea （P 〈 0.05）. KPS score had no difference, patients in observation group had a better quality of life （P 〈 0.05）; After treatment, CEA level of observation group was significantly decreased, while tile control group had no significant difference. Conclusion XELIRI regimen with tongtai decoction has a good efficacy and little side effects in patients with advanced colorectal cancer.